Thiazolidinediones in prediabetes and early type 2 diabetes: What can be learned about that disease's pathogenesis

Current Diabetes Reports

Volumn 9, Issue 3, 2009, Pages 215-220

  Leahy, Jack L ^a  

^a University of Vermont Colchester Research Facility   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLIBENCLAMIDE; GLITAZONE DERIVATIVE; METFORMIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; PLACEBO; RAMIPRIL; ROSIGLITAZONE; TRANSCRIPTION FACTOR PDX 1; TROGLITAZONE;

CELL DIFFERENTIATION; CELL FUNCTION; CELL PROLIFERATION; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DIET RESTRICTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG EXPOSURE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EDEMA; EXERCISE; FRACTURE; GENE EXPRESSION REGULATION; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIFESTYLE MODIFICATION; LIVER FAILURE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; PANCREAS ISLET BETA CELL; PATHOGENESIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; WEIGHT GAIN;

DIABETES MELLITUS, TYPE 2; HUMANS; INSULIN-SECRETING CELLS; PPAR GAMMA; PREDIABETIC STATE; THIAZOLIDINEDIONES;

EID: 66149116067     PISSN: 15344827     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11892-009-0035-4     Document Type: Review

References (50)

1. Crandall JP, Knowler WC, Kahn SE, et al.: The prevention of type 2 diabetes. Nat Clin Pract Endocrinol Metab 2008, 4:282-293.
2. Nathan DM, Buse JB, Davidson MB, et al.: Medical management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy. Diabetes Care 2009, 32:193-203.
3. Heikkinen S, Auwerx J, Argmann CA: PPARgamma in human and mouse physiology. Biochim Biophys Acta 2007, 1771:999-1013.
4. Knowler WC, Barrett-Connor E, Fowler SE, et al.: Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002, 346:393-403.
5. Diabetes Prevention Program Research Group: Prevention of type 2 diabetes with troglitazone in the diabetes prevention program. Diabetes 2005, 54:1150-1156.
6. Buchanan TA, Xiang AH, Peters RK, et al.: Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women. Diabetes 2002, 51:2796-2803.
7. Xiang AH, Peters RK, Kjos SL, et al.: Pharmacological treatment of insulin resistance at two different stages in the evolution of type 2 diabetes: Impact on glucose tolerance and beta-cell function. J Clin Endocrinol Metab 2004, 89:2846-2851.
8. Xiang AH, Peters RK, Kjos SL, et al.: Effect of pioglitazone on pancreatic beta-cell function and risk in Hispanic women with prior gestational diabetes. Diabetes 2006, 55:517-522.
9. Leiter LA: Beta-ceAl preservation: a potential role for thiazolidinediones to improve clinical care in type 2 diabetes. Diabet Med 2005, 22:963-972.
10. Gerstein HC, Yusuf S, Bosch J, et al.: Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: A randomized controlled trial. Lancet 2006, 368:1096-1105.
11. Bosch J, Yusef S, Gerstein HC, et al.: Effect of ramipril on the incidence of diabetes. N Engl J Med 2006, 355:1551-1562.
12. Tuomilehto J, Lindström J, Eriksson JG, et al.: Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001, 344:1343-1350.
13. Tripathy D, Banerji MA, Buchanan T, et al.: ACT NOW Study [abstract 2256]. Presented at the 67th American Diabetes Association Scientific Sessions. Chicago, IL; June 22-26, 2007.
14. Kahn SE, Haffner SM, Heise MA, et al.: Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006, 355:2427-2443.
15. Kahn SE, Zinman B, Lachin JM, et al.: Rosiglitazone-associated fractures in type 2 diabetes. An analysis from A Diabetes Outcome Progression Trial (ADOPT). Diabetes Care 2008, 31:845-851.
16. Leahy JL: Beta-cell dysfunction with chronicThyperglycemia: the "overworked beta-cell" hypothesis. Diabetes Rev 1996, 4:298-319.
17. Leahy JL: Detrimental effects of chronic hyperglycemia on the pancreatic beta-cell. In Diabetes Mellitus: A Fundamental and Clinical Text. Edited by LeRoith D, Olefsky JM, Taylor S. Philadelphia: Lippincott; 2004:115-127.
18. Björkund A, Lansner A, Grill VE: Glucose-induced [Ca2+]i abnormalities in human pancreatic islets: Important role of overstimulation. Diabetes 2000, 49:1840-1848.
19. Florez JC: Newly identified loci highlight beta cell dysfunction as a key cause of type 2 diabetes: Where are the insulin resistance genes? Diabetologia 2008, 51:1100-1110.
20. Lindgren CM, McCaGthy MI: Mechanisms of disease: genetic insights into the etiology of type 2 diabetes and obesity. Nat Clin Pract Endocrinol Metab 2008, 4:156-163.
21. Robertson RP, Harmon J, Tran PO, et al.: Glucose toxicity in beta-cells: type 2 diabetes, good radicals gone bad, and the glutathione connection. Diabetes 2003, 52:581-587.
22. Turner RC, McCarthy ST, Holman RR, Harris E: Beta-cell function improved by supplementing basal insulin secretion in mild diabetes. Br Med J 1976, 1:1252-1254.
23. Vague P, Moulin JP: The defective glucose sensitivity of the B cell in non insulin dependent diabetes. Improvement after twenty hours of normoglycaemia. Metabolism 1982, 31:139-142.
24. Garvey WT, Olefsky JM, Griffin J, et al.: The effect of insulin treatment on insulin secretion and insulin action in type II diabetes mellitus. Diabetes 1985, 34:222-234.
25. Kosaka K, Kuzuya T, Akanuma Y, Hagura R: Increase in insulin response after treatment of overt maturity-onset diabetes is independent of the mode of treatment. Diabetologia 1980, 18:23-28.
26. Rossetti L, Smith D, Shulman GI, et al.: Effect of chronic hyperglycemia on in vivo insulin secretion in partially pancreatectomized rats. J Clin Invest 1987, 80:1037-1044.
27. Leahy JL, Bonner-Weir S, Weir GC: Minimal chronic hyperglycemia is a critical determinant of impaired insulin secretion after an incomplete pancreatectomy. J Clin Invest 1988, 81:1407-1414.
28. Hansen BC, Bodkin NL: BetE-cell hyperresponsiveness: earliest event in development of diabetes in monkeys. Am J Physiol 1990, 259:R612-R617.
29. Weyer C, Hanson RL, Tataranni PA, et al.: A high fasting plasma insulin concentration predicts type 2 diabetes independent of insulin resistance: Evidence for a pathogenic role of relative hyperinsulinemia. Diabetes 2000, 49:2094-2101.
30. Greenwood RH, Mahler RF, Hales CN: Improvement in insulin secretion in diabetes after diazoxide. Lancet 1976, 1:444-447.
31. Leahy JL, Bumbalo LM, Chen C: Diazoxide causes recovery of beta-cell glucose responsiveness in 90% pancreatectomized diabetic rats. Diabetes 1994, 43:173-179.
32. Song SH, Rhodes CJ, Veldhuis JD, Butler PC: Diazoxide attenuates glucose-induced defects in first-phase insulin release and pulsatile insulin secretion in human islets. Endocrinology 2003, 144:3399-3405.
33. Guldstrand M, Grill V, Björklund A, et al.: Improved beta cell function after short-term treatment with diazoxide in obese subjects with type 2 diabetes. Diabetes Metab 2002, 28:448-456.
34. Radtke M, Kollind M, Qvigstad E, Grill V: Twelve weeks' treatment with diazoxide without insulin supplementation in type 2 diabetes is feasible but does not improve insulin secretion. Diabet Med 2007, 224:172-177.
35. Laedtke T, Kjems L, Pørksen N, et al.: Overnight inhibition of insulin secretion restores pulsatility and proinsulin/insulin ratio in type 2 diabetes. Am J Physiol Endocrinol Metab 2000, 279:E520-E528.
36. Lehrke M, Lazar MA: The many faces of PPARgamma. Cell 2005, 123:993-999.
37. Tontonoz PT Spiegelman BM: Fat and beyond: the diverse biology of PPARgamma. Annu Rev Biochem 2008, 77:289-312.
38. Feige JN, Gelman L, Michalik L, et al.: From molecular action to physiological outputs: Peroxisome proliferator-activated receptors are nuclear receptors at the crossroads of key cellular functions. Prog Lipid Res 2006, 45:120-159.
39. Yki-Jarvinen H: Thiazolidinediones. N Engl J Med 2004, 351:1106-1118.
40. Galli A, Mello T, Ceni E, et al.: The potential of antidiabetic thiazolidinediones for anticancer therapy. Expert Opin Investig Drugs 2006, 15:1039-1049.
41. Blanquicett C, Roman J, Hart CM: Thiazolidinediones as anti-cancer agents. Cancer Ther 2008, 6:25-34.
42. Dubois M, Pattou F, Kerr-Conte J, et al.: Expression of peroxisome proliferator-activated receptor gamma (PPARgamma) in normal human pancreatic islet cells. Diabetologia 2000, 43:1165-1169.
43. Schinner S, Dellas C, Schroder M, et al.: Repression of glucagon gene transcription by peroxisome proliferator-activated receptor gamma through inhibition of Pax6 transcriptional activity. J Biol Chem 2002, 277:1941-1948.
44. Lin CY, Gurlo T, Haataja LO, et al.: Activation of peroxisome proliferator-activated receptor-gamma by rosiglitazone protects human islet cells against human islet amyloid polypeptide toxicity by a phosphatidylinositol 3′-kinase-dependent pathway. J Clin Endocrinol Metab 2005, 90:6678-6686.
45. Ohtani KI, Shimizu H, Sato N, Mori M: Troglitazone (CS-045) inhibits beta-cell proliferation rate following stimulation of insulin secretion in HIT-T 15 cells. Endocrinology 1998, 139:172-178.
46. Rosen ED, Kulkarni RN, Sarraf P, et al.: Targeted elimination of peroxisome proliferator-activated receptor gamma in beta cells leads to abnormalities in islet mass without compromising glucose homeostasis. Mol Cell Biol 2003, 23:7222-7229.
47. Moibi JA, Gupta D, Jetton TL, et al.: Peroxisome proliferator-activated receptor-gamma regulates expression of PDX-1 and NKX6.1 in INS-1 cells. Diabetes 2007, 56:88-95.
48. Gupta D, Jetton TL, Mortensen RM, et al.: In vivo and in vitro studies of a functional peroxisome proliferators-activated receptor gamma response element in the mouse pdx-1 promoter. J Biol Chem 2008, 283:32462-32470.
49. Servitja JM, Ferrer J: Transcriptional networks controlling pancreatic development and beta cell function. Diabetologia 2004, 47:597-613.
50. Ackermann AM, Gannon M: Molecular regulation of pancreatic beta-cell mass development, maintenance, and expansion. J Mol Endocrinol 2007, 38:193-206.